ArticleMolecular neurobiology2026
Transcriptomics and Experiments Verified that Astaxanthin Reduces the Apoptosis of Nerve Cells in Ischemic Stroke by Inhibiting the Toll-like Receptor Signaling Pathway.
Article in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Inflammation is an important pathological process in ischemic stroke (IS). Astaxanthin (ATX) is a natural product with neuroprotection effects. However, the mechanism of ATX on anti-inflammatory after IS is not clear. The aim of this study was to investigate the mechanism of ATX on anti-inflammatory after IS. Male Sprague-Dawley rats were used to establish a model of middle cerebral artery occlusion (MCAO) on one side and were pre-treated with gavage of ATX for 7 days. One day after MCAO, behavioral tests were conducted on the rats, and the brain tissues were subsequently collected. Transcriptomic sequencing (differentially expressed genes with fold change > 1 or < - 1 and FDR P value < 0.05 were selected), flow cytometry, brain water content, Western blot, HE staining, immunohistochemistry and ELISA were analyzed to evaluate the brain damage. ATX treatment has improved the neurological deficits and reduced brain edema, cerebral infarction volume, the expression of tight junction protein occludin, and apoptosis. Also, ATX has reduced inflammation and apoptosis-related proteins such as TLR4, MyD88, NFκB, IL-1β, IL-6, Cyt C, and Caspase-3. The protective effect of ATX was inhibited by the TLR4 agonist RS 09. ATX can improve nerve damage after IS, and these protective effects were realized by anti-inflammatory and anti-apoptosis. ATX alleviates apoptosis and inflammation of IS by inhibiting the TLR4 pathway.
Indexed as
Identifiers
42050264What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.